Minoxidil 3.5% Topical Solution Hair Regrowth Treatment For Women 60ml/2floz
$9.00 Original price was: $9.00.$8.26Current price is: $8.26.
Active Ingredient: The active ingredient in this product is Minoxidil which can be compared to the active ingredient in Women’s Rogaine
Clinically Proven: When used twice a day as directed,Ulthimo Minoxidil Topical Solution reactivates hair follicles to stimulate regrowth
Dermatologist Recommended: Contains the number one dermatologist recommended OTC hair regrowth treatment active ingredient (of U.S. Physicians surveyed by an independent market research firm)
Unscented and Easy to Use: This discreet, unscented topical solution is easy to use with the enclosed child-resistant dropper
Regrowth Results: Hair regrowth may occur at 2 months with twice a day usage; some women may need to use this treatment for at least 3 months before seeing results
Ulthimo Minoxidil Topical Solution, 3.5 Percent is a hair regrowth treatment for women in an unscented, easy-to-use topical treatment that revitalizes hair follicles and is clinically proven to help regrow hair. Contains the number one dermatologist recommended OTC hair regrowth treatment active ingredient (of U.S. Physicians surveyed by an independent market research firm). For women who have a general thinning of hair on the top of the scalp. It takes time to regrow hair. Results may occur at 2 months with twice a day usage. For some women, you may need to use this product for at least 3 months before you see results. If you experience hair regrowth, continued use of this treatment is necessary or the hair loss will begin again.
Inactive Ingredients
alcohol, propylene glycol, purified water.
Active Ingredients
Minoxidil 3.5%
Biotin
Only logged in customers who have purchased this product may leave a review.
Q & A
Vendor Information
- Store Name: Mauriana
- Vendor: Mauriana
-
Address:
C124 benue plaza Tradefair
Ojo
Lagos
Nigeria -
4.52 rating from 42 reviewsRated 4.52 out of 5 based on 42 customer ratings








Reviews
There are no reviews yet.